AARD
Price
$3.95
Change
-$0.46 (-10.43%)
Updated
Oct 22 closing price
Capitalization
86.45M
21 days until earnings call
Intraday BUY SELL Signals
BCYC
Price
$3.64
Change
+$0.07 (+1.96%)
Updated
Oct 22 closing price
Capitalization
254.77M
6 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AARD vs BCYC

AARD vs BCYC Comparison Chart in %
View a ticker or compare two or three
VS
AARD vs. BCYC commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AARD is a Hold and BCYC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AARD with price predictions
Oct 22, 2026

Momentum Indicator for AARD turns negative, indicating new downward trend

AARD saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator turned negative. In 21 of the 23 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for AARD turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 17 similar instances when the indicator turned negative. In 14 of the 17 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AARD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for AARD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AARD's RSI Indicator exited the oversold zone, 6 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 15 of 16 cases where AARD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

Following a +17.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where AARD advanced for three days, in 87 of 100 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

AARD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.156) is normal, around the industry mean (2.973). P/E Ratio (-1.227) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. AARD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AARD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for BCYC with price predictions
Oct 22, 2026

BCYC's RSI Oscillator climbs out of oversold territory

The RSI Indicator for BCYC moved out of oversold territory on October 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 48 similar instances when the indicator left oversold territory. In 40 of the 48 cases the stock moved higher. This puts the odds of a move higher at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 69 cases where BCYC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for BCYC just turned positive on October 22, 2026. Looking at past instances where BCYC's MACD turned positive, the stock continued to rise in 34 of 47 cases over the following month. The odds of a continued upward trend are 72%.

Following a +4.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in 188 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCYC as a result. In 75 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

BCYC moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

BCYC broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BCYC entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.499) is normal, around the industry mean (2.973). P/E Ratio (-1.333) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. BCYC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BCYC: Fundamental Ratings
BCYC
OUTLOOK RATING
1..100
17
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
76
P/E GROWTH RATING
1..100
27
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AARDBCYC
RSI
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
72%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
83%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (AARD: $4.41 vs. BCYC: $3.64)
Brand notoriety: AARD and BCYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AARD: 182% vs. BCYC: 69%
Market capitalization -- AARD: $86.45M vs. BCYC: $254.77M
AARD [@Biotechnology] is valued at $86.45M. BCYC’s [@Biotechnology] market capitalization is $254.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AARD’s FA Score shows that 1 FA rating(s) are green while BCYC’s FA Score has 1 green FA rating(s).

  • AARD’s FA Score: 1 green, 4 red.
  • BCYC’s FA Score: 1 green, 4 red.
According to our system of comparison, both AARD and BCYC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AARD’s TA Score shows that 4 TA indicator(s) are bullish while BCYC’s TA Score has 4 bullish TA indicator(s).

  • AARD’s TA Score: 4 bullish, 4 bearish.
  • BCYC’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AARD is a better buy in the short-term than BCYC.

Price Growth

AARD (@Biotechnology) experienced а +13.66% price change this week, while BCYC (@Biotechnology) price change was +1.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

AARD is expected to report earnings on Nov 12, 2026.

BCYC is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
AARD
Daily Signal:
Gain/Loss:
BCYC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

AARD and

Correlation & Price change

A.I.dvisor tells us that AARD and PULM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AARD and PULM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AARD
1D Price
Change %
AARD100%
-10.43%
PULM - AARD
31%
Poorly correlated
-9.55%
TWST - AARD
30%
Poorly correlated
-9.16%
ACAD - AARD
29%
Poorly correlated
+0.59%
BCYC - AARD
28%
Poorly correlated
+1.96%
TSHA - AARD
28%
Poorly correlated
-2.79%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PRF56.400.08
+0.14%
Invesco RAFI US 1000 ETF (PRF)
ESUM30.72-0.08
-0.26%
Eventide Us Market ETF
SMIN67.07-0.32
-0.47%
iShares MSCI India Small Cap ETF (SMIN)
UXJA38.68-0.61
-1.55%
FT Vest U.S. Equity Uncapped Accelerator ETF - January (UXJA)
EHLS24.33-0.72
-2.86%
Even Herd Long Short ETF (EHLS)